Journal Browser

Journal Browser

Special Issue "Roles of Lipoxygenase in Human Health and Diseases"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 88

Special Issue Editor

Department of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA 95064, USA
Interests: role of lipoxygenase in inflammatory diseases; allosteric regulation; inhibitor discovery; biological relevance

Special Issue Information

Dear Colleagues, 

Lipoxygenases (LOXs) belong to the multigene family of dioxygenases containing non-heme iron in the active site of the enzyme. They catalyze the stereospecific insertion of molecular oxygen into the cis,cis-1,4-pentadiene configuration of polyunsaturated fatty acids, thus forming the corresponding hydroperoxide. Based on their positional specificity, lipoxygenases are categorized as 5-LOX, 8-LOX, 12-LOX, and 15-LOX isoenzymes, which differ not only in the position of oxidation but also in the chirality, essential for their biological activity.

LOXs, as a rate-limiting enzyme in the process of metabolizing arachidonic acid into oxylipins, such as leukotrienes (LT), exist in the human body and mediate the occurrence of inflammation. This important metabolic activity means that LOXs play an important role in a range of human diseases, such as cancer, stroke, obesity, diabetes, cardiovascular diseases, and neurodegenerative diseases. Given these implications of LOX participation in the pathogenesis of chronic inflammation diseases, considerable research in discovering novel effective inhibitors is currently underway.

Due to this emerging yet important role of LOXs, papers related to any molecular aspect of LOXs role in human health and disease will be considered for this Special Issue. For example, we will consider articles regarding novel LOX inhibitors and their mechanism, biosynthetic pathways involving LOXs, biomarkers based on LOX-derived metabolites, LOXs as therapeutic targets in various human diseases, and novel insights/future perspectives on LOX-related inflammatory diseases.

Prof. Dr. Theodore Holman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • lipoxygenase
  • leukotrienes
  • inflammation
  • cancer
  • stroke
  • obesity
  • diabetes, cardiovascular diseases
  • neurodegenerative diseases
  • inhibitors
  • biosynthesis
  • therapeutic targets

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop